Equity Advisory

Are looking for an honest, transparent and independent equity research and advisory? www.intelsense.in is run by Abhishek Basumallick for retail investors. Subscribe for long term wealth creation.

Thursday, 21 March 2013

Merck - Stable Pharma Major

I have been looking at some Pharma names recently. Let me put a disclaimer upfront. I am not very good at analyzing pharma companies. I am not able to differentiate between most of the companies who sell non-patented generic drugs in India.

Having said that, the numbers for Merck looked good. Below is a glimpse.

Market Cap: Rs. 1050 Cr
Current Price: Rs. 630.00
Book Value: Rs. 291.36
Stock P/E: 13.34
Debt to equity: 0.00
Price to book value: 2.16
Promoter Holding: 51.8%
  • Merck Limited was set up in India as Merck’s first Asian subsidiary in 1967. The Company operates both its pharmaceuticals & chemicals businesses in the country.
  • Dec'13 (Q4) quarter net profits & EPS have gone up by 58%; Revenues are up 31.8%
  • FY12 (year ending Dec) EPS is 47.2 vs 38.4 in Fy11 (Gain of 23%)

Problem Areas
  • Large part of the company's revenues comes from areas under govt price control, ability to pass on input cost escalations is not there. This can severely impact margins.
  • Company has a performance materials division which makes pigments and cosmetic actives, neither of which is core to the company's business.

Valuation
The company is likely to post a FY13 (Dec) EPS of close to 53-54. At 15 times, the stock can trade at around 800 levels, which is about 25% from current levels. So, not a screaming buy, but something worth looking into for stability and moderate returns over the short term.

Disclosure: I am not invested in Merck at this time. I am not yet decided whether to invest or not. Please do your own due diligence before investing.

No comments:

Post a Comment